Silencing of Rac1 modifies lung cancer cell migration, invasion and actin cytoskeleton rearrangements and enhances chemosensitivity to antitumor drugs.
about
AXL kinase as a novel target for cancer therapyPaxillin mutations affect focal adhesions and lead to altered mitochondrial dynamics: relevance to lung cancerMyosin Light Chain Kinase: A Potential Target for Treatment of Inflammatory DiseasesHsa-microRNA-101 suppresses migration and invasion by targeting Rac1 in thyroid cancer cells.The Rac Inhibitor EHop-016 Inhibits Mammary Tumor Growth and Metastasis in a Nude Mouse Model.RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancerSubpathway Analysis based on Signaling-Pathway Impact Analysis of Signaling PathwayMicroRNA-361-3p suppresses tumor cell proliferation and metastasis by directly targeting SH2B1 in NSCLC.Rac1 overexpression is correlated with epithelial mesenchymal transition and predicts poor prognosis in non-small cell lung cancer.TIPE2 suppresses angiogenesis and non-small cell lung cancer (NSCLC) invasiveness via inhibiting Rac1 activation and VEGF expression.The role of Rac1 in the regulation of NF-κB activity, cell proliferation, and cell migration in non-small cell lung carcinoma.Silencing Ras-Related C3 Botulinum Toxin Substrate 1 Inhibits Growth and Migration of Hypopharyngeal Squamous Cell Carcinoma via the P38 Mitogen-Activated Protein Kinase Signaling Pathway.shRNA-induced silencing of Ras-related C3 botulinum toxin substrate 1 inhibits the proliferation of colon cancer cells through upregulation of BAD and downregulation of cyclin D1.Inhibition of the Receptor Tyrosine Kinase AXL Restores Paclitaxel Chemosensitivity in Uterine Serous Cancer.Rac1 Modulates Endothelial Function and Platelet Aggregation in Diabetes Mellitus.Invasion and replication of Yersinia ruckeri in fish cell cultures.
P2860
Q26863442-88A1699E-6A2B-4562-83C5-756F336DCBF4Q30542819-E6402A76-24D2-408A-BCD2-011E64905BDDQ33715428-B0B4F18B-320E-4AE1-8233-6C0765D16F6AQ34141872-2EEB1D41-37DC-4B06-BF74-798D02C16F76Q34478364-16CF3628-6662-4317-8A2D-24181AD23DC8Q35051834-AEAC2B69-E707-4FE4-9D8F-BE34C9EEF1C4Q35711258-C6C5D4AE-F9F1-46D3-BDEC-E25E951C760AQ36890487-9BCC3BAC-98C8-4F65-95B4-FBD48D1ED487Q37427965-53FB9A3F-93B2-4DDE-86AE-0131271D6B96Q37641756-33A1FE72-8A3D-4E91-9FA5-50774E83307DQ39355557-97142FE9-9BED-43BC-AB40-9FBCCBCB489EQ49423049-FF92453A-8A58-4EDD-86CE-61D783992FCEQ49500445-6A742A13-7588-4E07-9EE4-28E5D99C33D1Q50113702-0E353C67-B5F2-45F3-B7D7-9C50950965F0Q52601658-61803D1A-9BDC-4527-B090-56501BBE8531Q52727587-43CFB5A2-B3CD-4AF6-AD77-63F37FC7EC69
P2860
Silencing of Rac1 modifies lung cancer cell migration, invasion and actin cytoskeleton rearrangements and enhances chemosensitivity to antitumor drugs.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Silencing of Rac1 modifies lun ...... ensitivity to antitumor drugs.
@en
Silencing of Rac1 modifies lun ...... ensitivity to antitumor drugs.
@nl
type
label
Silencing of Rac1 modifies lun ...... ensitivity to antitumor drugs.
@en
Silencing of Rac1 modifies lun ...... ensitivity to antitumor drugs.
@nl
prefLabel
Silencing of Rac1 modifies lun ...... ensitivity to antitumor drugs.
@en
Silencing of Rac1 modifies lun ...... ensitivity to antitumor drugs.
@nl
P2093
P356
P1476
Silencing of Rac1 modifies lun ...... ensitivity to antitumor drugs.
@en
P2093
De-Min Jiao
Hui-Zhen Hu
Qing-Hua Yao
Qing-Yong Chen
Yu-Quan Wu
P304
P356
10.3892/IJMM.2011.775
P50
P577
2011-08-11T00:00:00Z